Anti-DLL3 antibody drug conjugates for treating cancer
US10137204B2 · kind B2 · utility
6Cited by
47References
33Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 15, 2016 |
| Grant date | Nov 27, 2018 |
| Priority date | — |
| Expiry date | Nov 19, 2036 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/70596
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.